Clinical Trial Update: Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial investigating the combination of ixazomib and romidepsin in peripheral T-cell lymphoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Romidepsin (romidepsin)
• ixazomib (ixazomib)

Snippet

Sponsor: Ryan Wilcox | Conditions: Lymphoma, T-Cell, Peripheral | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING